Enqio

New Customer: Movetis

Movetis aims to become a leading pharmaceutical company focused on gastro-intestinal (GI) diseases. Movetis was founded in 2006 as a spin-off by senior managers and scientists of Janssen Pharmaceutica (Johnson & Johnson). And not without success: the company’s lead product Resolor® has recently received marketing approval from the European Commission; in addition to its lead product Resolor®, Movetis has a broad and novel portfolio of GI product candidates at different stages of development. Movetis went public in 2009 (Euronext Brussels). ENQIO welcomes Movetis as a new customer as from January 2010.